Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting

[1]  C. Roger,et al.  The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients , 2023, Antibiotics.

[2]  J. Briegel,et al.  Individualised dosing of antibiotics in ICU patients: timing, target and model selection matter , 2023, Intensive Care Medicine.

[3]  J. D. De Waele,et al.  Advancing precision-based antimicrobial dosing in critically ill patients , 2023, Intensive Care Medicine.

[4]  J. Roberts,et al.  Accuracy of a precision dosing software program for predicting antibiotic concentrations in critically ill patients. , 2022, Journal of Antimicrobial Chemotherapy.

[5]  L. Velly,et al.  Impact of piperacillin unbound fraction variability on dosing recommendations in critically ill patients , 2022, British journal of clinical pharmacology.

[6]  A. Karakus,et al.  Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial , 2022, Intensive Care Medicine.

[7]  R. Bellomo,et al.  Machines that help machines to help patients: optimising antimicrobial dosing in patients receiving extracorporeal membrane oxygenation and renal replacement therapy using dosing software , 2022, Intensive Care Medicine.

[8]  C. Landersdorfer,et al.  Research priorities towards precision antibiotic therapy to improve patient care. , 2022, The Lancet. Microbe.

[9]  P. Pickkers,et al.  An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients , 2022, Clinical Pharmacokinetics.

[10]  J. Roberts,et al.  Precision dosing software to optimise antimicrobial dosing: a systematic search and follow-up survey of available programs. , 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  L. Velly,et al.  Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients , 2022, Clinical Pharmacokinetics.

[12]  I. Spriet,et al.  The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis , 2022, Intensive Care Medicine.

[13]  P. Schlattmann,et al.  Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial , 2022, Intensive Care Medicine.

[14]  C. Sprung,et al.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 , 2021, Intensive Care Medicine.

[15]  Measurement of Free Plasma Concentrations of Beta-Lactam Antibiotics: An Applicability Study in Intensive Care Unit Patients: Erratum. , 2021, Therapeutic Drug Monitoring.

[16]  A. Marsot,et al.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses , 2021, Clinical Pharmacokinetics.

[17]  S. Wicha,et al.  From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics , 2021, Clinical pharmacology and therapeutics.

[18]  M. Vogeser,et al.  The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome , 2020, Journal of Intensive Care.

[19]  Z. Jiao,et al.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations , 2020, Clinical Pharmacokinetics.

[20]  J. Zander,et al.  The ONTAI study - a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units. , 2020, Journal of critical care.

[21]  M. Sawan,et al.  Towards wearable and implantable continuous drug monitoring: A review , 2020, Journal of Pharmaceutical Analysis.

[22]  J. Roberts,et al.  Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity. , 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  A. Tonna,et al.  Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia , 2020, Antimicrobial Agents and Chemotherapy.

[24]  D. Marriott,et al.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# , 2020, Intensive Care Medicine.

[25]  M. Storgaard,et al.  Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment , 2020, Antimicrobial Agents and Chemotherapy.

[26]  G. Urban,et al.  On-Site Therapeutic Drug Monitoring. , 2020, Trends in biotechnology.

[27]  S. Wicha,et al.  Impact of Inaccurate Documentation of Sampling and Infusion Time in Model-Informed Precision Dosing , 2020, Frontiers in Pharmacology.

[28]  R. Draenert,et al.  Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice , 2020, Antibiotics.

[29]  M. Weigand,et al.  Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience , 2019, Infection.

[30]  A. Verstraete,et al.  Measuring Unbound Versus Total Piperacillin Concentrations in Plasma of Critically Ill Patients: Methodological Issues and Relevance , 2019, Therapeutic drug monitoring.

[31]  M. Storgaard,et al.  Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered? , 2018, Antimicrobial Agents and Chemotherapy.

[32]  S. Lemeshow,et al.  Time to Treatment and Mortality during Mandated Emergency Care for Sepsis , 2017, The New England journal of medicine.

[33]  Brian T. Tsuji,et al.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections , 2017, Intensive Care Medicine.

[34]  M. Vogeser,et al.  Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study , 2016, Critical Care.

[35]  J. Starkopf,et al.  Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock , 2016, Acta anaesthesiologica Scandinavica.

[36]  M. Kollef,et al.  Time to Appropriate Antibiotic Therapy Is an Independent Determinant of Postinfection ICU and Hospital Lengths of Stay in Patients With Sepsis* , 2015, Critical care medicine.

[37]  R. Bellomo,et al.  A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics , 2015, Critical Care.

[38]  K. Klein,et al.  Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? , 2015, Critical Care.

[39]  Gary S Collins,et al.  Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement , 2015, BMC Medicine.

[40]  J. Rello,et al.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  K. Masui,et al.  Evaluation of the predictive performance of a pharmacokinetic model for propofol in Japanese macaques (Macaca fuscata fuscata). , 2013, Journal of veterinary pharmacology and therapeutics.

[42]  J. Gonçalves-Pereira,et al.  Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams , 2011, Critical care.

[43]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[44]  J. Roberts,et al.  Pharmacokinetic issues for antibiotics in the critically ill patient , 2009, Critical care medicine.

[45]  J. Schwartz.  The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology , 2007, Clinical pharmacology and therapeutics.

[46]  Rolf Rossaint,et al.  Epidemiology of sepsis in Germany: results from a national prospective multicenter study , 2007, Intensive Care Medicine.

[47]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[48]  S B Duffull,et al.  Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. , 1999, British journal of clinical pharmacology.

[49]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[50]  OUP accepted manuscript , 2022, Journal of Antimicrobial Chemotherapy.

[51]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .